**Download data set only | ****Download all Monolix project files**

In this case study we demonstrate how to implement and analyze a longitudinal MBMA model with Monolix and Simulx.

- Introduction
- Background
- Data selection, extraction and visualization
- Longitudinal mixed effect model description
- Set up of the model in Monolix
- Model development: Parameter estimation, model diagnosis, alternate model, covariate search, and final model
- Simulations for decision support
- Comparison of Canaki efficacy with drugs on the market
- Simulations of a Canaki versus Placebo clinical trial

- Conclusion
- Guidelines for implementing your own MBMA model

## Introduction

Due to the high costs of drug development, it is crucial to determine as soon as possible during the drug development process if the new drug candidate has a reasonable chance of showing clinical benefit compared to the other compounds already on the market. To help the decision makers in go/no-go decisions, model-based meta-analysis (MBMA) has been proposed. MBMA consists in using published **aggregate data from many studies** to develop a model and **support the decision process**. **Note that individual data are usually not available as only mean responses over entire treatment arms are reported in publications.**

Because in an MBMA approach one considers studies instead of individuals, the formulation of the problem as a mixed effect model differs slightly from the typical PK/PD formulation. **In this case study, we present how MBMA models can be implemented, analyzed and used for decision support in Monolix and Simulx. **

As an example, we focus on longitudinal data of the **clinical efficacy of drugs for rheumatoid arthritis (RA)**. The goal is to evaluate the efficacy of a drug in development (phase II) in comparison to two drugs already on the market. This case study is strongly inspired by the following publication:

Demin, I., Hamrén, B., Luttringer, O., Pillai, G., & Jung, T. (2012). Longitudinal model-based meta-analysis in rheumatoid arthritis: an application toward model-based drug development. Clinical Pharmacology and Therapeutics, 92(3), 352–9.

### Canakinumab, a drug candidate for rheumatoid arthritis

Rheumatoid arthritis (RA) is a complex auto-immune disease, characterized by swollen and painful joints. It affects around 1% of the population and evolves slowly (the symptoms come up over months). Patients are usually first treated with traditional disease-modifying anti-rheumatic drugs, the most common being methotrexate (MTX). If the improvement is too limited, patients can be treated with biologic drugs in addition to the MTX treatment. Although biologic drugs have an improved efficacy, remission is not complete in all patients. **To address this unmet clinical need, a new drug candidate, Canakinumab (abbreviated Canaki), has been developed at Novartis**. After a successful proof-of-concept study, a 12-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-finding phase IIB study with Canaki+MTX was conducted in patients with active RA despite stable treatment with MTX. In the study, Canaki+MTX was shown to be superior to MTX alone.

**We would like to compare the expected efficacy of Canaki with the efficacy of two other biologics already on the market, Adalimumab (abbreviated Adali) and Abatacept (abbreviated Abata)**. Several studies involving Adali and Abata have been published in the past (see list below). A typical endpoint in those studies is the **ACR20, i.e the percentage of patients achieving 20% improvement.** We focus in particular on longitudinal ACR20 data, measured at several time points after initiation of the treatment, and **we would like to use a mixed effect model to describe this data.**

### MBMA concepts

The formulation of longitudinal mixed effect models for *study-level data* differs from longitudinal mixed effect models for *individual-level data*. As detailed in

Ahn, J. E., & French, J. L. (2010). Longitudinal aggregate data model-based meta-analysis with NONMEM: Approaches to handling within treatment arm correlation. Journal of Pharmacokinetics and Pharmacodynamics, 37(2), 179–201.

to obtain the study-level model equations, one can write a non-linear mixed effect model for each individual (including inter-individual variability) and derive the study-level model by taking the mean response in each treatment group, i.e the average of the individual responses. In the simplistic case of linear models, the study-level model can be rewritten such that a **between-study variability (BSV), a between-treatment arm variability (BTAV) and a residual error appear**. Importantly, in this formulation, **the residual error and the between treatment arm variability are weighted by \(\sqrt{N_{ik}}\) **with \(N_{ik}\)_{ }the number of individuals in treatment arm k of study i. If the model is not linear, a study-level model cannot be easily derived from the individual-level model. Nevertheless, *one usually makes the approximation that the study-level model can also be described using between-study variability, between-treatment arm variability and a residual error term*.

This result can be understood in the following way: when considering studies which represent aggregated data, the **between-study variability represents the fact that the inclusion criteria vary from study to study**, thus leading to patient groups with slightly different mean characteristics from study to study. This aspect is independent of the number of individuals recruited. On the opposite,** the between-treatment arm variability represents the fact that when the recruited patients are split in two or more arms, the characteristics of the arms will not be perfectly the same**, because there is a finite number of individuals in each arm. The larger the arms are, the smaller the difference between the mean characteristics of the arms is, because one averages over a larger number. This is why the between-treatment arm variability is weighted by \(\sqrt{N_{ik}}\). **For the residual error, the reasoning is the same: as the individual-level residual error is averaged over a larger number of individuals, the study-level residual error decreases.**

The study-level model can thus be written in a way similar to the individual-level model, except that **we consider between-study variability and between-treatment arm variability instead of inter-individual variability and inter-occasion variability.** And in addition, the residual error and the between treatment arm variability are weighted by \(\sqrt{N_{ik}}\).

Before proposing a model for rheumatoid arthritis, let us first have a closer look at the data.

## Data selection, extraction and visualization

### Data selection

**To compare Canaki to Adali and Abata, we have searched for published studies involving these two drugs.** Reusing the literature search presented in Demin et al., we have selected only studies with inclusion criteria similar to the Canaki study, in particular: approved dosing regimens, and patients having an inadequate response to MTX. Compared to the Demin et al. paper, we have included two additional studies published later on. **In all selected studies, the compared treatments are MTX+placebo and MTX+biologic drug.**

The full list of used publications is:

- Weinblatt, M. E., et al. (2013). Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: Findings of a phase IIIb, multinational, prospective, randomized study.
*Arthritis and Rheumatism*, 65(1) - Genovese, M. C., at al. (2011). Subcutaneous abatacept versus intravenous abatacept: A phase IIIb noninferiority study in patients with an inadequate response to methotrexate.
*Arthritis and Rheumatism*, 63(10) - Kremer, J. M., et al. (2005). Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: Twelve-month results of a phase IIb, double-blind, randomized, placebo-controlled trial.
*Arthritis and Rheumatism*, 52(8), 2263–2271. - Kremer, J. M., et al. (2006). Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial.
*Annals of Internal Medicine*, 144(12), 865–76. - Schiff, M., et al. (2008). Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate.
*Annals of the Rheumatic Diseases*, 67(8), 1096–103. - Keystone, E. C., et al. (2004). Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled.
*Arthritis Rheum*, 50(5), 1400–1411. - Kim, H.-Y., et al. (2007). A randomized, double-blind, placebo-controlled, phase III study of the human anti-tumor necrosis factor antibody adalimumab administered as subcutaneous injections in Korean rheumatoid arthritis patients treated with methotrexate.
*APLAR Journal of Rheumatology*, 10(1), 9–16. - Weinblatt, M. E., et al. (2003). Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial.
*Arthritis and Rheumatism*, 48(1), 35–45.

### Data extraction

Using an online data digitizer application, **we have extracted the longitudinal ACR20 data of the 9 selected publications**. The information is recorded in a data file, together with additional information about the studies. The in house individual Canaki data from the phase II trial is averaged over the treatments arms to be comparable to the literature aggregate data. Below is a screenshot of the data file, and a description of the columns.

**STUDY:**index of the study/publication. (Equivalent to the ID column)**ARM:**0 for placebo arm (i.e MTX+placebo treatment), and 1 for biologic drug arm (MTX+biologic drug)**DRUG:**name of the drug administrated in the arm (placebo, adali, abata or canaki)**TIME:**time since beginning of the treatment, in weeks**ACR20:**percentage of persons on the study having an at least 20% improvement of their symptoms**Publication:**first author of the publication from which the data has been extracted**Narm:**number of individuals in the arm**TRT:**treatment studied in the study**DiseaseDuration:**mean disease duration (in years) in the arm at the beginning of the study**CReactiveProtein:**mean C-reactive protein level (in mg/dL)**SwollenJointCount:**mean number of swollen joints

### Data visualization

**To gain a better overview of this data set, we first plot it using Datxplore, the data visualization application of the MonolixSuite**. After having open Datxplore, we click on `Project > New project/data`

and then `Browse`

to select the data file. The data set columns are assigned in the following way:

Note that **the STUDY column is tagged as ID and the ARM column as OCCASION** as we will use the inter-individual and inter-occasion variability concepts of the MonolixSuite to define between-study and between-treatment arm variability instead. **All columns that may be used to stratify/color the plots must be tagged as either continuous or categorical covariate**, even if these columns will not be used in the model.

After having clicked `OK`

, the data appears in the Dataviewer tab. To better distinguish the treatments and arms, **we go to the Stratify tab and allocate the DRUG and TRT covariates. We then choose to split by TRT and color by DRUG**. We also arrange the layout in a single line and choose the option

`xEqualDomains`

in the `Settings`

tab. In the following figure, arms with biologic drug treatment appear in color (abata in blue, adali in red, canaki in green), while placebo arms appear in black. Note that even in the “placebo” arms the ACR20 improves over time, due to the MTX treatment. In addition, **we clearly see that the treatment MTX+biologic drug has a better (but not complete) efficacy compared to MTX+placebo.**For Canaki, which is the in house drug in development, only one study is available, the phase II trial.

**Given this data, does Canaki has a chance to be more effective than Adali and Abata?** To answer this question, we develop a longitudinal mixed effect model.

## Longitudinal mixed effect model description

Given the shape of the ACR20 over time, we propose an **Emax structural model**:

$$f(t)= \textrm{Emax}\frac{t}{t+\textrm{T50}}$$

Remember that the ACR20 is a fraction of responders, it is thus in the range 0-1 (or 0-100 if considering the corresponding percentage). In order to keep the model observations also in the range 0-1, we use a **logit transformation **for the observations \(y_{ijk}\):

$$\textrm{logit}(y_{ijk})=\textrm{logit}(\textrm{Emax}_{ik}\frac{t_j}{t_j+\textrm{T50}_{ik}})+\epsilon_{ijk}$$

with i the index over studies, j the index over time, and k the index over the treatment arms. \(\epsilon_{ijk}\) is the residual error, it is distributed according to

$$\epsilon_{ijk}\sim \mathcal{N}\left( 0,\frac{\sigma^2}{N_{ik}}\right)$$

with \(N_{ik}\) the number of individuals in treatment arm k of study i. Because our data is quite scarce and our interest is mainly on the Emax (efficacy), we choose to consider **between-study variability (BSV) and between treatment arm variability (BTAV) for Emax only.** For Emax parameter distribution, we select a logit distribution to keep its values between 0 and 1. We thus have:

$$\textrm{logit}(\textrm{Emax}_{ik})=\textrm{logit}(\textrm{Emaxpop}_{d})+\eta^{(0)}_{\textrm{E},i}+\eta^{(1)}_{\textrm{E},ik}$$

\(\eta^{(0)}_{\textrm{E},i}\) represents the BSV and \(\eta^{(1)}_{\textrm{E},ik}\) represents the BTAV.

For T50, we select a log-normal distribution and no random-effects:

$$\textrm{log}(\textrm{T50}_{ik})=\textrm{log}(\textrm{T50pop}_{d})$$

with Emaxpop_{d} and T50pop_{d } the typical population parameters, that depend on the administrated drug d. The BSV (index (0)) and BTAV (index (1)) terms for Emax have the following distributions:

$$\eta^{(0)}_{\textrm{E},i}\sim\mathcal{N}\left( 0,\omega_E^2\right) \quad \eta^{(1)}_{\textrm{E},ik}\sim\mathcal{N}\left( 0,\frac{\gamma_E^2}{N_{ik}}\right)$$

Note that the between-treatment arm variability and residual error are weighted by the number of individuals per arm, while the between-study variability is not, as explained in the section “MBMA concepts” above.

In the next section, we describe how to implement this model in Monolix.

## Set up of the model in Monolix

### For the error model

In Monolix, it is only possible to choose the error model among a pre-defined list. This does not allow to have a residual error model weighted by the square root of the number of individuals. **We will thus transform both the ACR20 observations of the data set and the model prediction in the following way, and use a constant error model**. Indeed we can rewrite:

$$\begin{array}{ccl}\textrm{logit}(y_{ijk})=\textrm{logit}(f(t_j,\textrm{Emax}_{ik},\textrm{T50}_{ik}))+\epsilon_{ijk} & \Longleftrightarrow & \textrm{logit}(y_{ijk})=\textrm{logit}(f(t_j,\textrm{Emax}_{ik},\textrm{T50}_{ik}))+\frac{\tilde{\epsilon}_{ijk}}{\sqrt{N_{ik}}} \\ & \Longleftrightarrow & \sqrt{N_{ik}} \times \textrm{logit}(y_{ijk})=\sqrt{N_{ik}} \times \textrm{logit}(f(t_j,\textrm{Emax}_{ik},\textrm{T50}_{ik}))+\tilde{\epsilon}_{ijk} \\ &\Longleftrightarrow& \textrm{transY}_{ijk}=\textrm{transf}(t_j,\textrm{Emax}_{ik},\textrm{T50}_{ik}))+\tilde{\epsilon}_{ijk} \end{array} $$

with

- \(\tilde{\epsilon}_{ijk}\) a constant (unweighted) residual error term,
- \(\textrm{transY}_{ijk}=\sqrt{N_{ik}} \times \textrm{logit}(y_{ijk})\) the transformed data,
- \(\textrm{transf}(t_j,\textrm{Emax}_{ik},\textrm{T50}_{ik}))=\sqrt{N_{ik}} \times \textrm{logit}(f(t_j,\textrm{Emax}_{ik},\textrm{T50}_{ik}))\) the transformed model prediction.

This data transformation is added to the data set, in the **column transY**.

At this stage, we can load the data set into Monolix. We create a new project and assign the columns as in Datxplore, except that **we now use the column transY as Y**. STUDY is tagged as ID, ARM as OCCASION, DRUG as CATEGORICAL COVARIATE, TIME as TIME, transY as Y, Narm as REGRESSOR, TRT as CATEGORICAL COVARIATE and DiseaseDuration, CReactiveProtein and SwollenJointCount as CONTINUOUS COVARIATE.

To match the observation transformation in the data set, we will have in the **Mlxtran model file**:

ACR20 = ... pred = logit(ACR20)*sqrt(Narm) OUTPUT: output = pred

In order to be available in the model, the data set column** Narm must be tagged as regressor**, and passed as argument in the input list:

[LONGITUDINAL] input = {..., Narm} Narm = {use=regressor}

In our example the number of individuals per arm (Narm) is constant over time. In case of dropouts or non uniform trials, **Narm may vary over time**. This will be taken into account in Monolix as, by definition, regressors can change over time.

### For the parameter distribution

Similarly to the error model, it is not possible to weight the BTAV directly via the Monolix GUI. As an alternative, **we can define separately the fixed effect (EmaxFE), the BSV random effect (etaBSVEmax) and the BTAV random effect (etaBTAVEmax) in the GUI and reconstruct the parameter value within the model file**. Because we have defined Narm as a regressor, we can use it to weight the BTAV terms. We also need to be careful about adding the random effects on the normally distributed transformed parameters. Here is the syntax for the structural model:

[LONGITUDINAL] input = {EmaxFE, T50, etaBSVEmax, etaBTAVEmax, Narm} Narm = {use=regressor} EQUATION: ; transform the Emax fixed effect (EmaxFE) to tEmax (normally distributed) tEmax = logit(EmaxFE) ; adding the random effects (RE) due to between-study variability and ; between arm variability, on the transformed parameters tEmaxRE = tEmax + etaBSVEmax + etaBTAVEmax/sqrt(Narm) ; transforming back to have EmaxRE with logit distribution (values between 0 and 1) EmaxRE = 1 / (1+ exp(-tEmaxRE) ) ; defining the effect ACR20 = EmaxRE * (t / (T50 + t)) ; adding a saturation to avoid taking logit(0) (undefined) when t=0 ACR20sat = max(ACR20, 0.01) ; transforming the effect ACR20 in the same way as the data pred = logit(ACR20sat)*sqrt(Narm) OUTPUT: output = pred

In addition to the steps already explained, we add a saturation ACR20sat=max(ACR20,0.01) to avoid having ACR20=0 when t=0, which would result in pred=logit(0) (which is undefined).

In the structural model tab, we click on `New model`

, copy-paste the code above and save the model. After having closed the editor, the model file can be selected via the `Browse`

button in the Monolix GUI, and the model appears below:

In the next tab `Statistical model | Tasks`

, we will define the statistical part of the model. **For the observation model**, we choose `constant`

from the list, according to the data transformation done.

**For the parameter distributions**, we choose a `logit`

distribution for EmaxFE, `lognormal`

for T50, and a `normal`

distribution for the random effects etaBSVEmax, and etaBTAVEmax.

Because with this model formulation **EmaxFE **represents only the fixed effects, **we need to disable the random effects for this parameter, as well as for T50. etaBTAVEmax is equivalent to inter-occasion variability, we thus disable the random effects at the STUDY level but enable them at the ARM level. **The random effects at both levels are thus set in the following way:

For **etaBSVEmax,** its distribution is \( \mathcal{N}(0,\omega^2) \) , we thus need to enforce its mean to be zero. **This is done in the initial estimates tab, using the cog-wheel button to fix etaBSVEmax_pop to 0. **We also do the same for etaBTAVEmax_pop.

### For the covariates

As a final step, we need to **add DRUG as a covariate on EmaxFE and T50, in order to estimate one EmaxFE and one T50 value for each treatment (placebo, adali, abata, and canaki)**. Before adding the DRUG column as covariate, we click on the `add covariate / discrete`

button and create a new covariate called tDRUG for which placebo is the reference category:

The newly created tDRUG is added on EmaxDE and T50. The other possible covariates will be investigated later on.

### Summary view

After this model set up, the `Statistical model | Tasks`

tab is:

## Model development

### Parameter estimation

#### Finding initial values

Before starting the parameter estimation, we first try to **find reasonable initial values.** In the** Initial estimates tab, Check initial estimates window**, we can adjust the initial parameter values by hand by looking at the agreement between the population prediction (red line) and the data (blue dots). We choose for instance EmaxFE=0.4 and T50=4.

#### Choosing the settings

We then **launch the parameter estimation task**. After around 110 iterations, the SAEM exploratory phase switches to the second phase, due to the automatic stopping criteria. The convergence looks rather good.

**To assess the convergence,** we can run the parameter estimation from different initial values and with a different random number sequence. To do so, we click on the **“assessment”** button and select “all”. 5 estimations run will be done using automatically drawn initial values.

The colored lines show the parameter estimates trajectories, while the black lines show the standard deviation. **We see that the parameters converge within the same standard error, except EmaxFE.** Parameters without variability, such as EmaxFE, may be harder to estimate. **Indeed, parameters with and without variability are not estimated in the same way. **The SAEM algorithm requires to draw parameter values from their marginal distribution, which exists only for parameters with variability.

**Several methods can be used to estimate the parameters without variability**. By default, these parameters are optimized using the Nelder-Mead simplex algorithm. As the performance of this method seems insufficient in our case, we will try another method. In the SAEM settings,

3 options are available in the “Methodology for parameters without variability” section:

**No variability**(default): optimization via Nelder-Mead simplex algorithm (Matlab’s fminsearch method)**Add decreasing variability**: an artificial variability is added for these parameters, allowing estimation via SAEM. The variability is progressively forced to zero, such that at the end of the estimation proces, the parameter has no variability.**Variability in the first stage**: during the first phase, an artificial variability is added and progressively forced to zero. In the second phase, the Nelder-Mead simplex algorithm is used.

We choose the “variability in the first stage” method (the other methods give similar results) and launch the convergence assessment again. **This time the convergence is satisfactory**.

#### Results

We can either directly look as the estimated values in the *_rep folders that have been generated during the convergence assessment, or redo the **parameter estimation** and the estimation of the **Fisher information matrix** (via linearization for instance) to get the standard errors.

**The estimated values** are the following:

As indicated by the p-value (calculated via a Wald test),** the Emax values for Abata and Adali are significantly different from the Emax for placebo**. On the opposite, given the data, the Emax value for Canaki is not significantly different from placebo. Note that when analyzing the richer *individual data* for Canaki, the efficacy of Canaki had been found significantly better than that of placebo (Alten, R. et al. (2011). Efficacy and safety of the human anti-IL-1β monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, Phase II, dose-finding study. *BMC Musculoskeletal Disorders*, 12(1), 153.). The T50 values are similar for all compounds except Adali.

**The between study variability of Emax is around 25%**. The between treatment arm variability is gamma_etaBTAVEmax = 2.21. In the model, the BTAV gets divided by the square root of the number of individuals per arm. If we consider a typical number of individual per arm of 200, **the between treatment arm variability is around 16%.**

### Model diagnosis

We next estimate the study parameters (i.e individual parameters via mode task) and generate** the graphics: no model mis-specification can be detected** in the individual fits, observations versus predictions, residuals, and other graphics:

Individual fits |
Observation versus prediction |
---|

**Note that all graphics use the transformed observations and transformed predictions.**

### Alternate models

One could try a more complex model including BSV and BTAV on T50 also. We leave this investigation as hands-on for the reader. The results are the following:** the difference in AIC and BIC between the 2 models is small and some standard errors of the more complex model are unidentifiable.** We thus decide to keep the simpler model.

### Covariate search

The between study variability originates from the different inclusion criteria from study to study. **To try to explain part of this variability, we can test adding the studied population characteristics as covariates**. The available population characteristics are the mean number of swollen joints, the mean C-reactive protein level and the mean disease duration.

As these covariates differ between arms, they appear in the IOV window. We first **transform the covariates** using a reference value:

We then include them one by one in the model on the Emax parameter. We can either **assess their significance using a Wald test** (p-value in the result file, calculated with the Fisher Information Matrix Task), **or a likelihood ratio**. The advantage of the Wald test is that it requires only one model to be estimated (the one with the covariate) while the likelihood ratio requires both models (with and without covariate) to be estimated. The p-values of the Wald test testing if the beta’s are zero are:

- Disease duration: p-value=0.76 (not significant)
- C-reactive protein level: p-value=0.33 (not significant)
- Swollen joint count: p-value=0.58 (not significant)

The likelihood ratio test also indicates that none of these covariates is significant. **We thus do not include these covariates in the model.**

### Final model overview

The final model has an Emax structural model, with between study and between treatment arm variability on Emax, and no variability on T50. No covariates are included. One Emax and one T50 population parameter per type of treatment (placebo, abata, adali and canaki) is estimated (via the beta parameters).

## Simulations for decision support

### Comparison of canaki efficacy with drugs on the market

We now would like to use the developed model to compare the efficacy of Canaki with the efficacy of Abata and Adali. **Has Canaki a chance to be more effective?** To answer this question, we will perform simulations using simulx, the simulation function of the mlxR R package, which is based on the same calculation engine as Monolix.

To compare the true efficacy (over an infinitely large population) of Canaki with Abata and Adali, we could simply compare the Emax values. **However the Emax estimates are marred with uncertainty, and this uncertainty should be taken into account**. **We will thus perform a large number of simulations for the 3 treatments, drawing the Emax population value from its uncertainty distribution**. The BSV, BTAV and residual error are removed from the model because we now consider an infinitely large population, to focus on the “true efficacy”.

Before running a simulation, we need to define: the model, the population parameter values, the output (what we observe and at which time points), and the treatment type (Abata, Adali, Canaki or placebo).

Without the BSV and BTAV,** the model is rewritten in the following way.** It can either be provided as a separate file, or directly in the R script using the inlineModel function of the mlxR package:

ACR20model <-inlineModel(" [LONGITUDINAL] input = {Emax, T50} EQUATION: ACR20 = Emax * (t / (T50 + t)) [COVARIATE] input = {tDRUG} tDRUG = {type=categorical, categories={abata, adali, canaki, placebo}} [INDIVIDUAL] input = {Emax_pop, beta_Emax_tDRUG_abata, beta_Emax_tDRUG_adali, beta_Emax_tDRUG_canaki, tDRUG, T50_pop, beta_T50_tDRUG_abata, beta_T50_tDRUG_adali, beta_T50_tDRUG_canaki} tDRUG = {type=categorical, categories={abata, adali, canaki, placebo}} DEFINITION: Emax = {distribution=logitnormal, typical=Emax_pop, covariate=tDRUG, coefficient={beta_Emax_tDRUG_abata, beta_Emax_tDRUG_adali, beta_Emax_tDRUG_canaki, 0}, no-variability} T50 = {distribution=lognormal, typical=T50_pop, covariate=tDRUG, coefficient={beta_T50_tDRUG_abata, beta_T50_tDRUG_adali, beta_T50_tDRUG_canaki, 0}, no-variability} ")

**The estimated parameter values** can either be directly written in a vector, or more conveniently **read from the Monolix output file**. The parameters must be an object of type named vector.

populationParameter <- read.table('./monolix_project/final_project/populationParameters.txt', header=TRUE, sep=',') param <- populationParameter[,"value"] names(param) <- populationParameter[,"parameter"]

**We next define the output**. In Monolix we were working with the transformed prediction because of the constraints on the error model. As here we neglect the error model, we can directly output the (untransformed) ACR20, every week:

out <- list(name='ACR20',time=seq(0,52,by=1))

We then need to define the applied treatments, that appear in the model as a categorical covariate. **As a first step, we simulate the ACR20 of each treatment using the estimated Emax and T50 values and neglecting the uncertainty**. We thus define 4 individuals (i.e studies), one with each treatment:

covariates <- data.frame(id=1:4, tDRUG=c('abata','adali','canaki','placebo'))

All the information is then passed to the **simulx function**, for simulation. The results are stored in the R object “res”.

res <- simulx(model=myModel, parameter=list(covariates,param), output = out)

**The results can then be plotted**, together with the original Canaki data (dots), using usual R functions:

We next would like to calculate a prediction interval for the true effect, taking into account the parameter uncertainty. **Using the simpopmlx function of the mlxR package, we can easily draw population parameters from the correlation matrix. **Note that with mlxR version 4.1.0, a check on overlapping occasions prevents the use of simpopmlx, which is therefore replaced by the fonction getPopUncertainty, provided as a separate file, which does the same as simpopmlx but without the checks.

# number of studies simulated for each of the three drugs, to take into account the uncertainty NBstudy <- 1000 # we will use simpopmlx to draw population parameters, taking into account the correlations paramWithUncertainty <- simpopmlx(n=4*NBstudy, project='./final_project.mlxtran') colnames(paramWithUncertainty)[1] <- "id"

The output and covariate definition, as well as the simulation, is similar to the previous case:

# define outputs out <- list(name='ACR20',time=seq(0,52,by=1)) outc<- list(name='tDRUG') # define covariates covariates <- data.frame(id=1:(4*NBstudy), tDRUG=rep(c('abata','adali','canaki','placebo'),each=NBstudy)) #simulation res2 <- simulx(model=myModel, parameter=list(covariates,paramWithUncertainty), output = list(out,outc))

After the simulation, the outputted data frames are slightly rearranged and plotted as **90% prediction interval using the prctilemlx function** of the mlxR package:

The prediction interval for Canaki is large, in accordance with its large uncertainty. Using the simulations, we calculate that:

- at week 12, there are 8% chances that Canaki is better than Abata and 5% chances it is better than Adali
- at week 52, there are 5.8% chances that Canaki is better than Abata and 15.6% chances it is better than Adali

We conclude that** chances are low that the efficacy of Canaki is better than that of the drugs already on the market**. In Demin et al., the authors conclude: *“ a decision was made not to pursue the RA indication. The integrated assessment of canakinumab data with the quantitative knowledge about current standard-of-care treatments supported this decision, given that the likelihood was low that canakinumab at current doses and regimen could provide incremental benefit to patients as compared with existing therapeutic options.*“

For the purpose of this case study, we will continue with clinical trial simulations of a Canaki versus Placebo trial.

### Simulations of a Canaki versus Placebo clinical trial

To simulate **a clinical trial of Canaki versus Placebo**, we this time need to take the BSV and BTAV into account, as well as the residual error, in addition to the uncertainty of the population parameters. The model code encompasses **the structural model (section [LONGITUDINAL]) as in Monolix, but also the covariates (section [COVARIATE]) and the individual parameters distributions (section [INDIVIDUAL])**, that in Monolix were defined via the GUI instead.

In addition, because simulx does not yet handle IOV, we define two etaBTAVEmax parameters in the [INDIVIDUAL] section, and use the first one for the first arm (occasion) and the second for the second arm (occasion). The arm index (0 for placebo and 1 for Canaki) is passed as regressor. The model is defined in the following:

### Click here to see the Simulx model file

myModel <-inlineModel(" [LONGITUDINAL] input = {Emax, T50, etaBSVEmax, etaBTAVEmax_OCCcanak,etaBTAVEmax_OCCplace, Narm, ARM, a} Narm = {use=regressor} ARM = {use=regressor} EQUATION: if ARM==0 ;ARM=0 corresponds to placebo etaBTAVEmax = etaBTAVEmax_OCCplace end if ARM==1 ;ARM=1 corresponds to canaki etaBTAVEmax = etaBTAVEmax_OCCcanak end ; transform Emax to tEmax (normally distributed) tEmax = logit(Emax) ; adding the random effects (RE) due to between-study variability and between arm variability, ; on the transformed parameters tEmaxRE = tEmax + etaBSVEmax + etaBTAVEmax/sqrt(Narm) ; transforming back to have EmaxRE with logit distribution (values between 0 and 1) EmaxRE = 1 / (1+ exp(-tEmaxRE) ) ; defining the effect ACR20 = EmaxRE * (t / (T50 + t)) ; adding a saturation to avoid taking logit(0) (undefined) when t=0 ACR20sat = max(ACR20, 0.000001) ; transforming the effect ACR20 in the same way as the data pred = logit(ACR20sat)*sqrt(Narm) DEFINITION: y= {distribution=normal, prediction=pred, sd=a} [COVARIATE] input = {tDRUG} tDRUG = {type=categorical, categories={placebo, canaki}} [INDIVIDUAL] input = {Emax_pop, beta_Emax_tDRUG_canaki, tDRUG, T50_pop, beta_T50_tDRUG_canaki, omega_etaBSVEmax, gamma1_etaBTAVEmax} tDRUG = {type=categorical, categories={placebo, canaki}} DEFINITION: Emax = {distribution=logitnormal, typical=Emax_pop, covariate=tDRUG, coefficient={0, beta_Emax_tDRUG_canaki}, no-variability} T50 = {distribution=lognormal, typical=T50_pop, covariate=tDRUG, coefficient={0, beta_T50_tDRUG_canaki}, no-variability} etaBSVEmax = {distribution=normal, typical=0, sd=omega_etaBSVEmax} etaBTAVEmax_OCCcanak = {distribution=normal, typical=0, sd=gamma1_etaBTAVEmax} etaBTAVEmax_OCCplace = {distribution=normal, typical=0, sd=gamma1_etaBTAVEmax} ")

All other simulx inputs are defined as before. After the simulation, **we calculate the ACR20 back from the transformed prediction**. We also calculate the standard deviation:

# transform the observation back to ACR20 observation res3$y$ObsEffect <- 1/(1+exp(-1*res3$y$y/sqrt(Narm))) # calculate the standard deviation res3$y$sd <- sqrt(1/Narm * res3$y$ObsEffect * (1-res3$y$ObsEffect))

The clinical trial simulation is plotted below:

To** test if Canaki is significantly more efficient than placebo**, we can test if the proportion of patient at week 52 reaching ACR20 with Canaki is significantly higher than the fraction with placebo. For this, **we perform a proportion test**, using the R prop.test() function:

# test for proportion at week 52 NbPlacebo=w52$ObsEffect[1]*Narm NbCanaki=w52$ObsEffect[2]*Narm prop.test(x=c(NbPlacebo,NbCanaki),n=c(Narm,Narm),alternative="less")

**The resulting p-value is 0.009, so we can consider that in this simulated clinical trial, Canaki turns out to be significantly more effective than placebo.**

If we redo the simulation, sometimes the difference will not be significative. To know what our chances are to get a successful trial (i.e the **power of the study**), we can simulate a large number of trials and count in how many cases the trial would have been successful. Here we would like to know **how the power of the study changes as we include more patients in the trial**. To do so, we simulate 1000 studies with 4 different numbers of patients (50, 100, 200 or 400). We then calculate the power of the study in the following way:

nbSuccessFullTrials=0 for(k in 1:length(dfCanak$id)){ tt <- prop.test(x=c(dfPlace$ObsEffect[k],dfCanak$ObsEffect[k])*Narm[i],n=rep(Narm[i],2), alternative="less") if(tt$p.value<0.05){ nbSuccessFullTrials=nbSuccessFullTrials+1 } } PowerStudy[i]=nbSuccessFullTrials/NBstudy

The results are the following:

Number of patients per arm | Power of the study |
---|---|

50 | 0.45 |

100 | 0.52 |

200 | 0.54 |

400 | 0.56 |

**Thus, even if we recrute 400 patients per arm, the power of the study would only be around 56%**.

All simulation scripts can be downloaded here.

## Conclusion

#### Model-informed drug development

Model based meta-analysis supports critical decisions during the drug development process. **In the present case, the model has shown that chances are low that Canaki performs better than two drugs already on the market.** As a consequence the development of this drug has been stopped, thus saving the high costs of the phase III clinical trials. **Clinical trial simulations based on a model can also be used to better design clinical trials**. In the last section, we have for instance shown how to choose the number of patients per arm, in order to reach a predefined statistical power.

#### MBMA with Monolix and Simulx

**This case study also aims at showing how Monolix and Simulx can be used to perform longitudinal model-based meta-analysis**. Contrary to the usual parameter definition in Monolix, the weighting of the between treatment arm variability imposes to split the parameters into their fixed term and their BSV and BTAV terms, and reform the parameter in the model file. Once the logic of this model formulation is understood, the model set up becomes straightforward. **The efficient SAEM algorithm for parameter estimation as well as the built in graphics then allow to efficiently analyze, diagnose and improve the model**.

**The inter-operability between Monolix and Simulx permits to carry the Monolix project over to Simulx to easily define and run clinical trial simulations**. Several levels of variability/uncertainty (variability in covariates, variability in individual parameters, uncertainty in population parameters) can be included in an effortless way, either directly in the model file, or via auxiliary functions such as simpopmlx.

#### Natural extensions

In this case study, continuous data were used. **Yet, the same procedure can be applied to other types of data such as count, categorical or time-to-event data**.

## Guidelines to implement your own MBMA model

### Setting up your data set

Your data set should usually contain the following columns:

**STUDY:**index of the study/publication. It is equivalent to the ID column for individual-level data.**ARM:**index of the arm (preferably continuous integers starting at 0). There can be an arbitrary number of arms (for instance several treated arms with different doses) and the order doesn’t matter. This column will be used as equivalent to the occasion OCC column.**TIME:**time of the observations**Y:**observations at the study level (percentage, mean response, etc)**transY**: transformed observations, for which the residual error model is constant**Narm:**number of individuals in the arm. Narm can vary over time**Covariates:**continuous or categorical covariates that are characteristics of the study or of the arm. Covariates must be constant over arms (appear in IOV window) or over studies (appear in main window).

#### Frequent questions about the data set

**Can dropouts (i.e. a time-varying number of individuals per arm) be taken into account?**Yes. This can be accounted for without difficulty as the number of subjects per arm (Narm) is passed as a regressor to the model file, a type that allow by definition variations over time.**Can there be several treated (or placebo) arms per study?**Yes. The different arms of a study are distinguished by a ARM index. For a given study, one can have observations for ARM=0, then observations for ARM=1, then observations for ARM=2. The index number has no special meaning (for instance ARM=0 can be the treated arm for study 1, and ARM=0 the placebo arm for study 2).**Why should I transform the observations?**The observations must be transformed such that an error model from the list (constant, proportional, combined, exponential, etc) can be used. In the example above, we have done two transformations: first we have used a logit transformation, such that the prediction of the fraction of individuals reaching ACR20 will remain in the 0-1 interval, even if by chance a large residual error term is drawn. If we instead consider a mean concentration of glucose for instance, we could use a log-transformation to ensure positive values. Second, we need to multiply each value by the square root of the number of individuals per arm. With this transformation, the standard deviation of the error term is the same for all studies and arms, and does not depend on the number of individuals per arm anymore.

### Setting up your model

The set up of your project can be done in four steps

- Split the parameters in several terms
- Make the appropriate transformation for the parameters
- Set the parameter definition in the Monolix interface
- Add the transformation of the prediction

#### Frequently asked questions on setting up the model

**Why should I split a parameter in several terms?**Because the standard deviation of the BTAV term must usually by weighted by the square root of the number of individuals per arm, this term must be handled as a separate parameter and added to the fixed effect within the model file. Moreover, the fixed effect and its BSV random effect might be split depending on the covariate definition.**How do I know in how many terms should I split my parameter?****If all covariates of interest are constant over studies: 2.**In this case, the parameters can be split into a (fixed effect + BSV) term and a (BTAV) term. The model file would for instance be (for a logit distributed parameter):[LONGITUDINAL] input = {paramFE_BSV, etaBTAVparam, Narm} Narm = {use=regressor} EQUATION: tparam = logit(paramFE_BSV) tparamRE = tparam + etaBTAVparam/sqrt(Narm) paramRE = 1 / (1+ exp(-tparamRE))

=> Impact on the interface: In the GUI, paramFE_BSV would have both a fixed effect and a BSV random effect. Covariates can be added on this parameter in the main window. The etaBTAVparam fixed effect should be enforced to zero, the BSV disabled and the BTAV in the IOV part enabled.

**If one covariate of interest is not constant over studies: 3.**This was the case for our case study (the DRUG covariates was constant over arms, not studies). Here, the parameters must be split into a fixed effect term, a BSV term and a BTAV term. The model file would for instance be (for a logit distributed parameter):[LONGITUDINAL] input = {paramFE, etaBSVparam, etaBTAVparam, Narm} Narm = {use=regressor} EQUATION: tparam = logit(paramFE) tparamRE = tparam + etaBSVparam + etaBTAVparam/sqrt(Narm) paramRE = 1 / (1+ exp(-tparamRE))

=> Impact on the interface In the GUI, paramFE has only a fixed effect (BSV random effect must be disabled in the variance-covariance matrix). Covariates can be added on this parameter in the IOV window. The fixed effect value of etaBSVparam must be enforced to zero. The etaBTAVparam fixed effect should be enforced to zero too, the BSV disabled and the BTAV in the IOV part enabled.

**Why shouldn’t I add covariates on the etaBTAVparam in the IOV window?**Covariates can be added on etaBTAVparam in the IOV window. Yet, because the value of etaBTAVparam will be divided by the square root of the number of individuals in the model file, the covariate values in the data set must be transformed to counter-compensate. This may not always be feasible:**If the covariate is categorical (as the DRUG on our example), it is not possible**to compensate and thus the user should not add the covariate on the etaBTAVparam in the GUI. A splitting in 3 terms is needed.**If the covariate is continuous (weight for example), it is possible to counter-compensate.**Thus, if you add the covariates on the etaBTAVparam in the GUI,**the covariate column in the data set must be multiplied by \(\sqrt{N_{ik}}\) beforehand.**This is a drawback, however this modeling has less parameters without variability and may thus converge more easily.

**How should I transform the parameter depending on its distribution?**Depending on the original parameter distribution, the parameter must first be transformed as in the following cases:**For a parameter with a normal distribution**, called paramN for example, we would have done the following:; no transformation on paramN as it is normally distributed tparamN = paramN ; adding the random effects (RE) due to between-study and between arm variability, on the transformed parameter tparamNRE = tparamN + etaBSVparamN + etaBTAVparamN/sqrt(Narm) ; no back transformation as tparamNRE already has a normal distribution paramNRE = tparamNRE

Note that the two equalities are not necessary but there for clarity of the code.

**For a parameter with a log-normal distribution**, called paramLog for example (or T50 in the test case), we would have done the following:; transformation from paramLog (log-normally distributed) to tparamLog (normally distributed) tparamLog = log(paramLog) ; adding the random effects (RE) due to between-study and between arm variability, on the transformed parameter tparamLogRE = tparamLog + etaBSVparamLog + etaBTAVparamLog/sqrt(Narm) ; transformation back to have paramLogRE with a log-normal distribution paramLogRE = exp(tparamLogRE)

**For a parameter with a logit-normal distribution**, called paramLogit for example (or Emax in the test case), we would have done the following:; transformation from paramLogit (logit-normally distributed) to tparamLogit (normally distributed) tparamLogit = logit(paramLogit) ; adding the random effects (RE) due to between-study and between arm variability, on the transformed parameter tparamLogitRE = tparamLogit + etaBSVparamLogit + etaBTAVparamLogit/sqrt(Narm) ; transformation back to have paramLogitRE with a logit-normal distribution paramLogitRE = 1 / (1+ exp(-tparamLogitRE))

**How do I set up the GUI?**Depending which option has been chosen, the fixed effects and/or the BSV random effects and/or the BTAV random effects of the model parameters (representing one or several terms of the full parameter) must be enforced to 0. Random effects can be disabled by clicking on the RANDOM EFFECTS column and fixed effects by choosing “fixed” after a click in the initial estimates.**Why and how do I transform the prediction?**The model prediction must be transformed in the same way as the observations of the data set, using the column Narm passed as regressor.

### Parameter estimation

The splitting of the parameters into several terms may introduce model parameters without variability. These parameters cannot be estimated using the main SAEM routine, but instead are optimized using alternative routines. Several of them are available in Monolix, under the settings of SAEM. If the method by default leads to poor convergence, we recommend to test the other methods.

### Model analysis

**All graphics are displayed using the transformed observations and predictions**. These are the right quantities to diagnose the model using the “Observation versus prediction” and “Scatter plot of the residuals”, “distribution of the residuals” and graphics. For the individuals fits and VPC, it may also be interesting to look at the non-transformed observations and predictions. These graphics can be redone in R using the simulx function of the mlxR package. The other diagnostic plots (“Individual parameters vs covariates”, “Distribution over the individual parameters”, “Distribution of the random effects”, and “Correlation of the random effects”) are not influenced by the transformation of the data.